U.S., March 18 -- ClinicalTrials.gov registry received information related to the study (NCT07476898) titled 'Precision Reperfusion Therapy for Disabling Minor Stroke With Large Vessel Occlusion Beyond Time Window' on March 10.
Brief Summary: To verify the efficacy and safety of intravenous tenecteplase (TNK) in patients with disabling minor stroke and large vessel occlusion (LVO) within a 4.5-24 hour time window.
Study Start Date: March 01
Study Type: INTERVENTIONAL
Condition:
Stroke
Intervention:
DRUG: Tenecteplase (0.25mg/kg)
Tenecteplase (0.25 mg/kg, intravenous bolus, maximum dose 25 mg) + Delayed dual antiplatelet therapy (initiated 24 hours after thrombolysis: Aspirin 100 mg orally once daily + Clopidogrel 75 mg orally once d...